Podcasts about pathological

Uncovers a powerful relationship between pathology and money: beginning in the nineteenth century, the severity of mental illness was measured against a patient's economic productivity. Madness and Enterprise: Psychiatry, Economic Reason, and the Emergence of Pathological Value (U Chicago Press, 2024) reveals the economic norms embedded within psychiatric thinking about mental illness in the North Atlantic world. Over the course of the nineteenth century, various forms of madness were subjected to a style of psychiatric reasoning that was preoccupied with money. Psychiatrists across Western Europe and the United States attributed financial and even moral value to an array of pathological conditions, such that some mental disorders were seen as financial assets and others as economic liabilities. By turning to economic conduct and asking whether potential patients appeared capable of managing their financial affairs or even generating wealth, psychiatrists could often bypass diagnostic uncertainties about a person's mental state. Through an exploration of the intertwined histories of psychiatry and economic thought, Nima Bassiri shows how this relationship transformed the very idea of value in the modern North Atlantic, as the most common forms of social valuation—moral value, medical value, and economic value—were rendered equivalent and interchangeable. If what was good and what was healthy were increasingly conflated with what was remunerative (and vice versa), then a conceptual space opened through which madness itself could be converted into an economic form and subsequently redeemed—and even revered. Nima Bassiri is assistant professor of literature at Duke University, where he is also the codirector of the Institute for Critical Theory. Morteza Hajizadeh is a Ph.D. graduate in English from the University of Auckland in New Zealand. His research interests are Cultural Studies; Critical Theory; Environmental History; Medieval (Intellectual) History; Gothic Studies; 18th and 19th Century British Literature. YouTube channel. Twitter. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/intellectual-history

Uncovers a powerful relationship between pathology and money: beginning in the nineteenth century, the severity of mental illness was measured against a patient's economic productivity. Madness and Enterprise: Psychiatry, Economic Reason, and the Emergence of Pathological Value (U Chicago Press, 2024) reveals the economic norms embedded within psychiatric thinking about mental illness in the North Atlantic world. Over the course of the nineteenth century, various forms of madness were subjected to a style of psychiatric reasoning that was preoccupied with money. Psychiatrists across Western Europe and the United States attributed financial and even moral value to an array of pathological conditions, such that some mental disorders were seen as financial assets and others as economic liabilities. By turning to economic conduct and asking whether potential patients appeared capable of managing their financial affairs or even generating wealth, psychiatrists could often bypass diagnostic uncertainties about a person's mental state. Through an exploration of the intertwined histories of psychiatry and economic thought, Nima Bassiri shows how this relationship transformed the very idea of value in the modern North Atlantic, as the most common forms of social valuation—moral value, medical value, and economic value—were rendered equivalent and interchangeable. If what was good and what was healthy were increasingly conflated with what was remunerative (and vice versa), then a conceptual space opened through which madness itself could be converted into an economic form and subsequently redeemed—and even revered. Nima Bassiri is assistant professor of literature at Duke University, where he is also the codirector of the Institute for Critical Theory. Morteza Hajizadeh is a Ph.D. graduate in English from the University of Auckland in New Zealand. His research interests are Cultural Studies; Critical Theory; Environmental History; Medieval (Intellectual) History; Gothic Studies; 18th and 19th Century British Literature. YouTube channel. Twitter. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/american-studies

Uncovers a powerful relationship between pathology and money: beginning in the nineteenth century, the severity of mental illness was measured against a patient's economic productivity. Madness and Enterprise: Psychiatry, Economic Reason, and the Emergence of Pathological Value (U Chicago Press, 2024) reveals the economic norms embedded within psychiatric thinking about mental illness in the North Atlantic world. Over the course of the nineteenth century, various forms of madness were subjected to a style of psychiatric reasoning that was preoccupied with money. Psychiatrists across Western Europe and the United States attributed financial and even moral value to an array of pathological conditions, such that some mental disorders were seen as financial assets and others as economic liabilities. By turning to economic conduct and asking whether potential patients appeared capable of managing their financial affairs or even generating wealth, psychiatrists could often bypass diagnostic uncertainties about a person's mental state. Through an exploration of the intertwined histories of psychiatry and economic thought, Nima Bassiri shows how this relationship transformed the very idea of value in the modern North Atlantic, as the most common forms of social valuation—moral value, medical value, and economic value—were rendered equivalent and interchangeable. If what was good and what was healthy were increasingly conflated with what was remunerative (and vice versa), then a conceptual space opened through which madness itself could be converted into an economic form and subsequently redeemed—and even revered. Nima Bassiri is assistant professor of literature at Duke University, where he is also the codirector of the Institute for Critical Theory. Morteza Hajizadeh is a Ph.D. graduate in English from the University of Auckland in New Zealand. His research interests are Cultural Studies; Critical Theory; Environmental History; Medieval (Intellectual) History; Gothic Studies; 18th and 19th Century British Literature. YouTube channel. Twitter. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/psychology

Uncovers a powerful relationship between pathology and money: beginning in the nineteenth century, the severity of mental illness was measured against a patient's economic productivity. Madness and Enterprise: Psychiatry, Economic Reason, and the Emergence of Pathological Value (U Chicago Press, 2024) reveals the economic norms embedded within psychiatric thinking about mental illness in the North Atlantic world. Over the course of the nineteenth century, various forms of madness were subjected to a style of psychiatric reasoning that was preoccupied with money. Psychiatrists across Western Europe and the United States attributed financial and even moral value to an array of pathological conditions, such that some mental disorders were seen as financial assets and others as economic liabilities. By turning to economic conduct and asking whether potential patients appeared capable of managing their financial affairs or even generating wealth, psychiatrists could often bypass diagnostic uncertainties about a person's mental state. Through an exploration of the intertwined histories of psychiatry and economic thought, Nima Bassiri shows how this relationship transformed the very idea of value in the modern North Atlantic, as the most common forms of social valuation—moral value, medical value, and economic value—were rendered equivalent and interchangeable. If what was good and what was healthy were increasingly conflated with what was remunerative (and vice versa), then a conceptual space opened through which madness itself could be converted into an economic form and subsequently redeemed—and even revered. Nima Bassiri is assistant professor of literature at Duke University, where he is also the codirector of the Institute for Critical Theory. Morteza Hajizadeh is a Ph.D. graduate in English from the University of Auckland in New Zealand. His research interests are Cultural Studies; Critical Theory; Environmental History; Medieval (Intellectual) History; Gothic Studies; 18th and 19th Century British Literature. YouTube channel. Twitter. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/new-books-network

Uncovers a powerful relationship between pathology and money: beginning in the nineteenth century, the severity of mental illness was measured against a patient's economic productivity. Madness and Enterprise: Psychiatry, Economic Reason, and the Emergence of Pathological Value (U Chicago Press, 2024) reveals the economic norms embedded within psychiatric thinking about mental illness in the North Atlantic world. Over the course of the nineteenth century, various forms of madness were subjected to a style of psychiatric reasoning that was preoccupied with money. Psychiatrists across Western Europe and the United States attributed financial and even moral value to an array of pathological conditions, such that some mental disorders were seen as financial assets and others as economic liabilities. By turning to economic conduct and asking whether potential patients appeared capable of managing their financial affairs or even generating wealth, psychiatrists could often bypass diagnostic uncertainties about a person's mental state. Through an exploration of the intertwined histories of psychiatry and economic thought, Nima Bassiri shows how this relationship transformed the very idea of value in the modern North Atlantic, as the most common forms of social valuation—moral value, medical value, and economic value—were rendered equivalent and interchangeable. If what was good and what was healthy were increasingly conflated with what was remunerative (and vice versa), then a conceptual space opened through which madness itself could be converted into an economic form and subsequently redeemed—and even revered. Nima Bassiri is assistant professor of literature at Duke University, where he is also the codirector of the Institute for Critical Theory. Morteza Hajizadeh is a Ph.D. graduate in English from the University of Auckland in New Zealand. His research interests are Cultural Studies; Critical Theory; Environmental History; Medieval (Intellectual) History; Gothic Studies; 18th and 19th Century British Literature. YouTube channel. Twitter. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/critical-theory

Uncovers a powerful relationship between pathology and money: beginning in the nineteenth century, the severity of mental illness was measured against a patient's economic productivity. Madness and Enterprise: Psychiatry, Economic Reason, and the Emergence of Pathological Value (U Chicago Press, 2024) reveals the economic norms embedded within psychiatric thinking about mental illness in the North Atlantic world. Over the course of the nineteenth century, various forms of madness were subjected to a style of psychiatric reasoning that was preoccupied with money. Psychiatrists across Western Europe and the United States attributed financial and even moral value to an array of pathological conditions, such that some mental disorders were seen as financial assets and others as economic liabilities. By turning to economic conduct and asking whether potential patients appeared capable of managing their financial affairs or even generating wealth, psychiatrists could often bypass diagnostic uncertainties about a person's mental state. Through an exploration of the intertwined histories of psychiatry and economic thought, Nima Bassiri shows how this relationship transformed the very idea of value in the modern North Atlantic, as the most common forms of social valuation—moral value, medical value, and economic value—were rendered equivalent and interchangeable. If what was good and what was healthy were increasingly conflated with what was remunerative (and vice versa), then a conceptual space opened through which madness itself could be converted into an economic form and subsequently redeemed—and even revered. Nima Bassiri is assistant professor of literature at Duke University, where he is also the codirector of the Institute for Critical Theory. Morteza Hajizadeh is a Ph.D. graduate in English from the University of Auckland in New Zealand. His research interests are Cultural Studies; Critical Theory; Environmental History; Medieval (Intellectual) History; Gothic Studies; 18th and 19th Century British Literature. YouTube channel. Twitter. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/medicine

Greedy Random Start Algorithms: From TSP to Daily LifeKey Algorithm ConceptsComputational Complexity ClassificationsConstant Time O(1): Runtime independent of input size (hash table lookups)"The holy grail of algorithms" - execution time fixed regardless of problem sizeExamples: Dictionary lookups, array indexing operationsLogarithmic Time O(log n): Runtime grows logarithmicallyEach doubling of input adds only constant timeDivides problem space in half repeatedlyExamples: Binary search, balanced tree operationsLinear Time O(n): Runtime grows proportionally with inputMost intuitive: One worker processes one item per hour → two items need two workersExamples: Array traversal, linear searchQuadratic O(n²), Cubic O(n³), Exponential O(2ⁿ): Increasingly worse runtimeQuadratic: Nested loops (bubble sort) - practical only for small datasetsCubic: Three nested loops - significant scaling problemsExponential: Runtime doubles with each input element - quickly intractableFactorial Time O(n!): "Pathological case" with astronomical growthBrute-force TSP solutions (all permutations)4 cities = 24 operations; 10 cities = 3.6 million operationsFundamentally impractical beyond tiny inputsPolynomial vs Non-Polynomial TimePolynomial Time (P): Algorithms with O(nᵏ) runtime where k is constantO(n), O(n²), O(n³) are all polynomialConsidered "tractable" in complexity theoryNon-deterministic Polynomial Time (NP)Problems where solutions can be verified in polynomial timeExample: "Is there a route shorter than length L?" can be quickly verifiedEncompasses both easy and hard problemsNP-Complete: Hardest problems in NPAll NP-complete problems are equivalent in difficultyIf any NP-complete problem has polynomial solution, then P = NPNP-Hard: At least as hard as NP-complete problemsExample: Finding shortest TSP tour vs. verifying if tour is shorter than LThe Traveling Salesman Problem (TSP)Problem Definition and IntractabilityFormal Definition: Find shortest possible route visiting each city exactly once and returning to originComputational Scaling: Solution space grows factorially (n!)10 cities: 181,440 possible routes20 cities: 2.43×10¹⁸ routes (years of computation)50 cities: More possibilities than atoms in observable universeReal-World Challenges:Distance metric violations (triangle inequality)Multi-dimensional constraints beyond pure distanceDynamic environment changes during executionGreedy Random Start AlgorithmStandard Greedy ApproachMechanism: Always select nearest unvisited cityTime Complexity: O(n²) - dominated by nearest neighbor calculationsMemory Requirements: O(n) - tracking visited cities and current pathKey Weakness: Extreme sensitivity to starting conditionsGets trapped in local optimaProduces tours 15-25% longer than optimal solutionVisual metaphor: Getting stuck in a valley instead of reaching mountain bottomRandom Restart EnhancementCore Innovation: Multiple independent greedy searches from different random starting citiesImplementation Strategy: Run algorithm multiple times from random starting points, keep best resultStatistical Foundation: Each restart samples different region of solution spacePerformance Improvement: Logarithmic improvement with iteration countImplementation Advantages:Natural parallelization with minimal synchronizationDeterministic runtime regardless of problem instanceNo parameter tuning required unlike metaheuristicsReal-World ApplicationsUrban NavigationTraffic Light Optimization: Avoiding getting stuck at red lightsGreedy approach: When facing red light, turn right if that's greenLocal optimum trap: Always choosing "shortest next segment"Random restart equivalent: Testing multiple routes from different entry pointsImplementation example: Navigation apps calculating multiple route optionsEconomic Decision MakingOnline Marketplace Selling:Problem: Setting optimal price without complete market informationLocal optimum trap: Accepting first reasonable offerRandom restart approach: Testing multiple price points simultaneously across platformsJob Search Optimization:Local optimum trap: Accepting maximum immediate salary without considering growth trajectoryRandom restart solution: Pursuing multiple different types of positions simultaneouslyGoal: Optimizing expected lifetime earnings vs. immediate compensationCognitive StrategyKey Insight: When stuck in complex decision processes, deliberately restart from different perspectiveImplementation Heuristic: Test multiple approaches in parallel rather than optimizing a single pathExpected Performance: 80-90% of optimal solution quality with 10-20% of exhaustive search effortCore PrinciplesProbabilistic Improvement: Multiple independent attempts increase likelihood of finding high-quality solutionsBounded Rationality: Optimal strategy under computational constraintsSimplicity Advantage: Lower implementation complexity enables broader applicationCross-Domain Applicability: Same mathematical principles apply across computational and human decision environments

Chapters 00:00 Introduction and Current Work 02:51 Shockwave Therapy: Efficacy and Mechanisms 06:07 Understanding Tendon Pathologies 09:00 Calcification and Adaptation in Tendons 11:55 The Role of Shockwave in Clinical Practice 15:12 Platelet-Rich Plasma (PRP) Insights 18:06 Stem Cells and Tendon Healing 20:57 Adjuncts in Tendon Rehabilitation 23:48 Heel Wedges: Evidence and Application 27:06 Loading Strategies for Tendinopathy 30:04 Compression and Tendon Mechanics 32:56 The Importance of Loading in Rehabilitation 35:51 Tendon Stiffness: Heavy Loads vs. Plyometrics 42:01 Understanding Tendon Loading Mechanisms 45:25 Isometric vs. Eccentric Loading for Tendon Adaptation 48:23 Maximal Eccentrics: Techniques and Applications 51:45 Fluid Movement and Tendon Health 55:35 The Role of Metabolism in Tendon Adaptation 01:01:10 The Complexity of Tendon Pathology 01:06:29 The Dynamics of Fluid Movement in Tendons 01:11:11 Plyometrics vs. Isometrics: Strain and Adaptation 01:14:05 Blood Flow Restriction Training and Tendon Adaptation 01:18:21 Metabolic Factors in Tendon Healing   Takeaways Peter Malairis is a full-time professor at Monash University. Recent research shows shockwave therapy is ineffective for tendon pain. Calcification in tendons may be an adaptive response. PRP injections do not outperform placebo treatments. Stem cell therapy lacks sufficient evidence for tendon healing. Adjunct therapies should be accessible, cheap, and safe. Heel wedges have shown significant effects in treating Achilles tendinopathy. Loading strategies must be tailored to individual patient needs. Tendon stiffness is primarily improved through heavy loading. Fluid movement within tendons is essential for adaptation. Loading the tendon heavier leads to better fluid movement. Isometrics are crucial for early rehabilitation stages. Heavy maximal eccentrics are key for long-term adaptation. Fluid movement impacts stress relaxation in tendons. Tendon stiffness increases with appropriate loading. Metabolic health is essential for tendon adaptation. Pathological tendons may require different loading strategies. Fluid movement can help reduce pain and improve function. Plyometrics may not provide sufficient strain for adaptation. Blood flow restriction can be effective for tendon rehabilitation.     Notes: https://jackedathlete.com/podcast-131-tendons-with-peter-malliaras/

Dr. Neeraj Agarwal and Dr. Peter Hoskin discuss key abstracts in GU cancers from the 2025 ASCO Genitourinary Cancers Symposium, including novel therapies in prostate, bladder, and kidney cancer and the impact of combination therapies on patient outcomes. TRANSCSRIPT Dr. Neeraj Agarwal: Hello, and welcome to the ASCO Daily News Podcast. I'm Dr. Neeraj Agarwal, the director of the Genitourinary Oncology Program and professor of medicine at the Huntsman Cancer Institute at the University of Utah, and editor-in-chief of ASCO Daily News. Today, we'll be discussing practice-informing abstracts and other key advances in GU oncology featured at the 2025 ASCO Genitourinary Cancers Symposium. Joining me for this discussion is Dr. Peter Hoskin, the chair of this year's ASCO GU Symposium. Dr. Hoskin is a professor in clinical oncology in the University of Manchester and honorary consultant in clinical oncology at the Christie Hospital, Manchester, and University College Hospital London, in the United Kingdom. Our full disclosures are available in the transcript of this episode. Peter, thank you for joining us today. Dr. Peter Hoskin: Thank you so much, Neeraj. I am very pleased to be here. Dr. Neeraj Agarwal: The GU meeting highlighted remarkable advancements across the spectrum of GU malignancies. What stood out to you as the most exciting developments at the ASCO GU Symposium?  Dr. Peter Hoskin: The theme of this year's meeting was "Driving Innovation, Improving Patient Care," and this reflected ASCO GU's incredible milestone in GU cancer research over the years. We were thrilled to welcome almost 6,000 attendees on this occasion from over 70 countries, and most of them were attending in person and not online, although this was a hybrid meeting. Furthermore, we had more than 1,000 abstract submissions. You can imagine then that it fostered fantastic networking opportunities and facilitated valuable knowledge and idea exchanges among experts, trainees, and mentees. So, to start I'd like to come back to you for a second because the first day started with a focus on prostate cancer and some of the key clinical trials. And congratulations to you, Neeraj, on sharing the data from the TALAPRO-2 trial, which we were eagerly awaiting. I'd love to get your thoughts on the data that you presented. Could you tell us more about that trial, Abstract LBA18?  Dr. Neeraj Agarwal: Yes, Peter, I agree with you. It was such an exciting conference overall and thank you for your leadership of this conference. So, let's talk about the TALAPRO-2 trial. First of all, I would like to remind our audience that the combination of talazoparib plus enzalutamide was approved by the U.S. FDA in June 2023 in patients with metastatic castration-resistant prostate cancer harboring HRR gene alterations, after this combination improved the primary endpoint of radiographic progression-free survival compared to enzalutamide alone in the randomized, double-blind, placebo-controlled, multi-cohort phase 3 TALAPRO-2 trial. In the abstract I presented at ASCO GU 2025, we reported the final overall survival data, which was a key alpha-protected secondary endpoint in cohort 1, which enrolled an all-comer population of patients with mCRPC. So, at a median follow-up of around 53 months, in the intention-to-treat population, the combination of talazoparib plus enzalutamide significantly reduced the risk of death by 20% compared to enzalutamide alone, with a median OS of 45.8 months in the experimental arm versus 37 months in the control arm, which was an active control arm of enzalutamide. This improvement was consistent in patients with HRR alterations with a hazard ratio of 0.54 and in those with non-deficient or unknown HRR status, with a hazard ratio of 0.87. In a post hoc analysis, the hazard ratio for OS was 0.78 favoring the combination in those patients who did not have any HRR gene alteration in their tumors by both tissue and ctDNA testing. Consistent with the primary analysis, the updated rPFS data also favored the experimental arm with a median rPFS of 33.1 compared to 19.5 months in the control arm, and a hazard ratio of 0.667. No new safety signals were identified with extended follow-up. Thus, TALAPRO-2 is the first PARP inhibitor plus ARPI study to show a statistically significant and a clinically meaningful improvement in OS compared to standard-of-care enzalutamide as first-line treatment in patients with mCRPC unselected for HRR gene alterations. Dr. Peter Hoskin: Thank you, Neeraj. That's a great summary of the data presented and very important data indeed. There was another abstract also featured in the same session, Abstract 20, titled “Which patients with metastatic hormone-sensitive prostate cancer benefit more from androgen receptor pathway inhibitors? STOPCAP meta-analyses of individual participant data.” Neeraj, could you tell us more about this abstract? Dr. Neeraj Agarwal: Absolutely, I would be delighted to. So, in this meta-analysis, Dr. David Fischer and colleagues pooled individual participant data from different randomized phase 3 trials in the mHSPC setting to assess the potential ARPI effect modifiers and determine who benefits more from an ARPI plus ADT doublet. The primary outcome was OS for main effects and PFS for subgroup analyses. Prostate cancer specific survival was a sensitivity outcome. The investigators pooled data from 11 ARPI trials and more than 11,000 patients. Overall, there was a clear benefit of adding an ARPI on both OS and PFS, with hazard ratios of 0.66 and 0.51, respectively, representing a 13% and 21% absolute improvement at 5 years, respectively, with no clear difference by the class of agent. When stratifying the patients by age group, the effects of adding an ARPI on OS and PFS were slightly smaller in patients older than 75, than in those younger than 65, or aged between 65 and 75 years. Notably, in the trials assessing the use of abiraterone, we saw very little OS effects in the group of patients older than 75, however there was some benefit maintained in prostate-cancer specific survival, suggesting that other causes of death may be having an impact. The effects of the other ARPIs, or ‘lutamides' as I would call them, were similar across all three age subgroups on both OS and PFS. Therefore, the majority of patients with mHSPC benefit from the addition of ARPIs, and the benefits/risks of abiraterone and other ‘amides' must be considered in older patients.  Dr. Peter Hoskin: Thanks, Neeraj. Another great summary relevant to our day-to-day practice. Of course, there's ongoing collection of individual patient data from other key trials, which will allow robust comparison of ARPI doublet with triplet therapy (including docetaxel), guiding more personalized treatment.   Dr. Neeraj Agarwal: I agree with you, Peter, we need more data to help guide personalized treatment for patients with mHSPC and potentially guide de-escalation versus escalation strategies. Now, moving on to a different setting in prostate cancer, would you like to mention Abstract 17 titled, “Overall survival and quality of life with Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in poor-risk, metastatic, castration-resistant prostate cancer in ENZA-p (ANZUP 1901),” presented by Dr. Louise Emmett? Dr. Peter Hoskin: Of course I will. So, ENZA-p was a multicenter, open-label, randomized, phase 2 trial conducted in Australia. It randomized 163 patients into adaptive doses (2 or 4 cycles) of Lu-PSMA-617 plus enzalutamide versus enzalutamide alone as first-line treatment in PSMA-PET-CT-positive, poor-risk, mCRPC. The interim analysis of ENZA-p with median follow-up 20 months showed improved PSA-progression-free survival with the addition of Lu-PSMA-617 to enzalutamide. Here, the investigators reported the secondary outcomes, overall survival, and health-related quality of life (HRQOL). After a median follow up of 34 months, overall survival was longer in the combination arm compared to the enzalutamide arm, with a median OS of 34 months compared to 26 months; with an HR of 0.55. Moreover, the combination improved both deterioration-free survival and health-related quality of life indicators for pain, fatigue, physical function, and overall health and quality of life compared to the control arm. Consistent with the primary analysis, the rPFS also favored the experimental arm with a median rPFS of 17 months compared to 14 months with a HR of 0.61. So, the addition of LuPSMA improved overall survival, and HRQOL in patients with high-risk mCRPC. Dr. Neeraj Agarwal: Thank you, Peter. Great summary, and promising results with Lu-177 and ARPI combination in first line treatment for mCRPC among patients who had two or more high risk features associated with early enzalutamide failure. Before we move on to bladder cancer, would you like to tell us about Abstract 15 titled, “World-wide oligometastatic prostate cancer (omPC) meta-analysis leveraging individual patient data (IPD) from randomized trials (WOLVERINE): An analysis from the X-MET collaboration,” presented by Dr. Chad Tang?  Dr. Peter Hoskin: Sure. So, with metastatic-directed therapy (MDT), we have a number of phase 2 studies making up the database, and the X-MET collaboration aimed to consolidate all randomized data on oligometastatic solid tumors. This abstract presented pooled individual patient data from all the published trials involving patients with oligometastatic prostate cancer who received MDT alongside standard of care (SOC) against SOC alone. The analysis included data from five trials, encompassing 472 patients with oligometastatic prostate cancer, and followed for a median of 41 months. Patients were randomly assigned in a 1:1 ratio to receive either MDT plus SOC or SOC alone. The addition of MDT significantly improved PFS. The median PFS was 32 months with MDT compared to 14.9 months with SOC alone, with an HR of 0.45. Subgroup analyses further confirmed the consistent benefits of MDT across different patient groups. Regardless of factors like castration status, receipt of prior primary treatment, stage, or number of metastases, MDT consistently improved PFS. In patients with mHSPC, MDT significantly delayed the time to castration resistance by nine months, extending it to a median of 72 months compared to 63 months in the SOC group with an HR of 0.58. In terms of OS, the addition of MDT improved the 48-month survival rate by 12%, with OS rates of 87% in the MDT+SOC group compared to 75% in the SOC alone group. Dr. Neeraj Agarwal: Thank you, Peter. These data demonstrate that adding MDT to systemic therapy significantly improves PFS, rPFS, and castration resistance-free survival, reinforcing its potential role in the treatment of oligometastatic prostate cancer. So, let's switch gears to bladder cancer and start with Abstract 658 reporting the OS analysis of the CheckMate-274 trial. Would you like to tell us about this abstract?  Dr. Peter Hoskin: Yes, sure, Neeraj. This was presented by Dr. Matt Milowsky, and it was additional efficacy outcomes, including overall survival, from the CheckMate-274 trial which evaluated adjuvant nivolumab versus placebo in patients with high-risk muscle-invasive bladder cancer after radical surgery. The phase 3 trial previously demonstrated a significant improvement in disease-free survival with nivolumab. With a median follow-up of 36.1 months, disease-free survival was longer with nivolumab compared to placebo across all patients with muscle-invasive bladder cancer, reducing the risk of disease recurrence or death by 37%. Among patients who had received prior neoadjuvant cisplatin-based chemotherapy, nivolumab reduced this risk by 42%, whilst in those who had not received chemotherapy, the risk was reduced by 31%. Overall survival also favored nivolumab over placebo, reducing the risk of death by 30% in all patients with muscle-invasive bladder cancer and by 52% in those with tumors expressing PD-L1 at 1% or higher. Among patients who had received prior neoadjuvant chemotherapy, nivolumab reduced the risk of death by 26%, whilst in those who had not received chemotherapy, the risk was reduced by 33%. Alongside this, the safety profile remained consistent with previous findings. Dr. Neeraj Agarwal: Thank you, Peter, for such a nice overview of this abstract. These results reinforce adjuvant nivolumab as a standard of care for high-risk muscle-invasive bladder cancer, offering the potential for a curative outcome for our patients. Dr. Peter Hoskin: I agree with you Neeraj. Perhaps you would like to mention Abstract 659 titled, “Additional efficacy and safety outcomes and an exploratory analysis of the impact of pathological complete response (pCR) on long-term outcomes from NIAGARA.” Dr. Neeraj Agarwal: Of course. Dr. Galsky presented additional outcomes from the phase 3 NIAGARA study, which evaluated perioperative durvalumab combined with neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer. The study previously demonstrated a significant improvement in event-free survival and overall survival with durvalumab compared to chemotherapy alone, with a manageable safety profile and no negative impact on the ability to undergo radical cystectomy. Among the 1,063 randomized patients, those who received durvalumab had a 33% reduction in the risk of developing distant metastases or death and a 31% reduction in the risk of dying from bladder cancer compared to those who received chemotherapy alone. More patients who received durvalumab achieved a pathological complete response at the time of surgery with 37% compared to 28% in the chemotherapy-alone group. Patients who achieved a pathological complete response had better event-free survival and overall survival compared to those who did not. In both groups, durvalumab provided additional survival benefits, reducing the risk of disease progression or death by 42% and the risk of death by 28% in patients with a pathological complete response, while in those patients without a pathological complete response, the risk of disease progression or death was reduced by 23% and the risk of death by 16% when durvalumab was added to the chemotherapy. Immune-mediated adverse events occurred in 21% of patients in the durvalumab group compared to 3% in the chemotherapy-alone group, with grade 3 or higher events occurring in 3% compared to 0.2%. The most common immune-related adverse events included hypothyroidism in 10% of patients treated with durvalumab compared to 1% in the chemotherapy-alone group, and hyperthyroidism in 3% versus 0.8%. At the time of the data cutoff, these adverse events had resolved in 41% of affected patients in the durvalumab group and 44% in the chemotherapy-alone group. Dr. Peter Hoskin: Thank you, Neeraj, for the great summary. These findings further support the role of perioperative durvalumab as a potential standard of care for patients with muscle-invasive bladder cancer. Dr. Neeraj Agarwal: I concur with your thoughts, Peter. Before wrapping up the bladder cancer section, would you like to mention Abstract 664 reporting updated results from the EV-302 trial, which evaluated enfortumab vedotin in combination with pembrolizumab compared to chemotherapy as first-line treatment for patients with previously untreated locally advanced or metastatic urothelial carcinoma? Dr. Peter Hoskin: Yes, of course. Dr. Tom Powles presented updated findings from the EV-302 study, and in this abstract presented 12 months of additional follow-up for EV-302 (>2 y of median follow-up) and an exploratory analysis of patients with confirmed complete response (cCR). The study had a median follow-up of 29.1 months and previously demonstrated significant improvements in progression-free survival and overall survival with enfortumab vedotin and pembrolizumab. This is now the standard of care in global treatment guidelines. Among the 886 randomized patients, enfortumab vedotin and pembrolizumab reduced the risk of disease progression or death by 52% and the risk of death by 49% compared to chemotherapy. The survival benefit was consistent regardless of cisplatin eligibility or the presence of liver metastases. The confirmed objective response rate was higher with enfortumab vedotin and pembrolizumab at 67.5% compared to 44.2% with chemotherapy. The median duration of response was 23.3 months with enfortumab vedotin and pembrolizumab compared to 7.0 months with chemotherapy. A complete response was achieved in 30.4% of patients in the enfortumab vedotin and pembrolizumab group compared to 14.5% in the chemotherapy group, with the median duration of complete response not yet reached in the enfortumab vedotin and pembrolizumab group compared to 15.2 months in the chemotherapy group. Severe treatment-related adverse events occurred in 57.3% of patients treated with enfortumab vedotin and pembrolizumab compared to 69.5% in the chemotherapy group, while in patients who achieved a complete response, severe adverse events occurred in 61.7% of those treated with enfortumab vedotin and pembrolizumab compared to 71.9% with chemotherapy. Treatment-related deaths were reported in 1.1% of patients treated with enfortumab vedotin and pembrolizumab compared to 0.9% with chemotherapy, with no treatment-related deaths occurring in those who achieved a complete response. These findings clearly confirm the durable efficacy of enfortumab vedotin and pembrolizumab, reinforcing its role as the standard of care for the first-line treatment of patients with locally advanced or metastatic urothelial carcinoma, and no new safety concerns have been identified. Dr. Neeraj Agarwal: Thank you for this great summary. Moving on to kidney cancer, let's talk about Abstract 439 titled, “Nivolumab plus cabozantinib (N+C) vs sunitinib (S) for previously untreated advanced renal cell carcinoma (aRCC): Final follow-up results from the CheckMate-9ER trial.” Dr. Peter Hoskin: Sure. Dr. Motzer presented the final results from the phase 3 CheckMate-9ER trial, which compared the combination of cabozantinib and nivolumab against sunitinib in previously untreated advanced renal cell carcinoma. The data after more than five years follow-up show that the combination therapy provided sustained superior efficacy compared to sunitinib. In terms of overall survival, we see an 11-month improvement in median OS, 46.5 months for the cabo-nivo versus 35.5 months for sunitinib and a 42% reduction in the risk of disease progression or death, with median progression-free survival nearly doubling – that's 16.4 months in the combination group and 8.3 months with sunitinib. Importantly, the safety profile was consistent with the known safety profiles of the individual medicines, with no new safety concerns identified. Dr. Neeraj Agarwal: Great summary, Peter. These data further support the efficacy of cabo-nivo combination therapy in advanced renal cell carcinoma, which is showing a 11-month difference in overall survival. Dr. Peter Hoskin: Neeraj, before wrapping up this podcast, would you like to tell us about Abstract 618? This is titled “Prospective COTRIMS (Cologne trial of retroperitoneal lymphadenectomy in metastatic seminoma) trial: Final results.” Dr. Neeraj Agarwal: Sure, Peter. I would be delighted to. Dr Heidenrich from the University of Cologne in Germany presented the COTRIMS data evaluating retroperitoneal LN dissection in patients with clinical stage 2A/B seminomas. Seminomas are classified as 2A or B when the disease spreads to the retroperitoneal lymph nodes of up to 2 cm (CS IIA) or of more than 2 cm to up to 5 cm (CS 2B) in maximum diameter, respectively. They account for 10-15% of seminomas and they are usually treated with radiation and chemotherapy. However, radiation and chemo can be associated with long-term toxicities such as cardiovascular toxicities, diabetes, solid cancers, leukemia, particularly for younger patients. From this standpoint, Dr Heidenrich and colleagues evaluated unilateral, modified template, nerve-sparing retroperitoneal lymph node dissection as a less toxic alternative compared to chemo and radiation. They included 34 patients with negative AFP, beta-HCG, and clinical stage 2A/B seminomas. At a median follow-up of 43.2 months, the trial demonstrated great outcomes: a 99.3% treatment-free survival rate and 100% overall survival, with only four relapses. Antegrade ejaculation was preserved in 88% of patients, and severe complications such as grade 3 and 4 were observed in 12% of patients. Pathological analysis revealed metastatic seminoma in 85% of cases, with miR371 being true positive in 23 out of 24 cases and true negative in 100% of cases. It appears to be a valid biomarker for predicting the presence of lymph node metastases. These findings highlight retroperitoneal lymph node dissection is feasible; it has low morbidity, and excellent oncologic outcomes, avoiding overtreatment in 80% of patients and sparing unnecessary chemotherapy or radiotherapy in 10-15% of cases. Dr. Peter Hoskin: Great summary and important data on retroperitoneal lymphadenectomy in metastatic seminoma. These findings will help shape clinical practice. Any final remarks before we conclude today's podcast? Dr. Neeraj Agarwal: Before wrapping up this podcast, I would like to say that we have reviewed several abstracts addressing prostate, bladder, kidney cancers, and seminoma, which are impacting our medical practices now and in the near future. Peter, thank you for sharing your insights with us today. These updates are undoubtedly exciting for the entire GU oncology community, and we greatly appreciate your valuable contribution to the discussion and your leadership of the conference. Many thanks. Dr. Peter Hoskin: Thank you, Neeraj. Thank you for the opportunity to share this information more widely. I'm aware that whilst we have nearly 6,000 delegates, there are many other tens of thousands of colleagues around the world who need to have access to this information. And it was a great privilege to chair this ASCO GU25. So, thank you once again, Neeraj, for this opportunity to share more of this information that we discussed over those few days. Dr. Neeraj Agarwal: Thank you, Peter. And thank you to our listeners for joining us today. You will find links to the abstracts discussed today on the transcript of this episode. Finally, if you value the insights that you hear on the ASCO Daily News podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity or therapy should not be construed as an ASCO endorsement.  Find out more about today's speakers:   Dr. Neeraj Agarwal    @neerajaiims    Dr. Peter Hoskin Follow ASCO on social media:      @ASCO on Twitter      ASCO on Bluesky  ASCO on Facebook      ASCO on LinkedIn      Disclosures: Dr. Neeraj Agarwal: Consulting or Advisory Role: Pfizer, Bristol-Myers Squibb, AstraZeneca, Nektar, Lilly, Bayer, Pharmacyclics, Foundation Medicine, Astellas Pharma, Lilly, Exelixis, AstraZeneca, Pfizer, Merck, Novartis, Eisai, Seattle Genetics, EMD Serono, Janssen Oncology, AVEO, Calithera Biosciences, MEI Pharma, Genentech, Astellas Pharma, Foundation Medicine, and Gilead Sciences Research Funding (Institution): Bayer, Bristol-Myers Squibb, Takeda, Pfizer, Exelixis, Amgen, AstraZeneca, Calithera Biosciences, Celldex, Eisai, Genentech, Immunomedics, Janssen, Merck, Lilly, Nektar, ORIC Pharmaceuticals, Crispr Therapeutics, Arvinas Dr. Peter Hoskin: Research Funding (Institution): Varian Medical Systems, Astellas Pharma, Bayer, Roche, Pfizer, Elekta, Bristol Myers  

In this week's episode of The TTL Podcast, Mon-Chaio and Andy delve into Ron Westrom's influential paper, "A Typology of Organizational Cultures." The hosts unpack the compelling insights and frameworks posited by Westrom, which categorize organizational cultures into Pathological, Bureaucratic, and Generative types. Mon-Chaio and Andy also share personal anecdotes and practical examples, such as dealing with software bugs, to illustrate the distinctions between local fix and inquiry-based approaches. They highlight the critical role of leadership and the importance of having a curious and improvement-focused mindset.References A typology of organisational cultures Accelerate S1E14: The Undeserved Malignment of Bureaucracy Culture Series (Part 1, Part 2, Part 3)

This podcast summaries the article 'Computed tomography of the equine caudal spine and pelvis. Pathological findings in 56 clinical cases (2018–2023)'.

Gilda Simonet and Barbara Wainwright The Power of Now - A Guide to Spiritual Enlightenment with Gilda and Barbara

In this episode, Sarah and her former co-host, Jacob, discuss the possible hypothetical outcomes of Donald Trump learning the practice of mindfulness. Would he lie less? Would he treat women better? Would he still have run for president? How would a mindfulness practice change the thinking of someone like Donald Trump? Sarah also shares some revealing research about people with narcissistic traits practicing mindfulness. The results of these studies might surprise you. They certainly perplexed the researchers who conducted the trials.  Please share this episode if you like the content!Here is a link to an article outlining the various types of narcissism: https://tinyurl.com/ycks747n“Do bigger egos mean bigger presence? Facets of grandiose narcissism and mindfulness” Current Psychology; 2022 “Pathological narcissism and psychological distress: The mediating effects of vitality, initiative, and mindfulness” Personality and Individual Differences; 2022“Does mindfulness meditation increase empathy? An experiment” Self and Identity; 2017Important links:Sarah's Mindfulness Coaching website: http://www.sarahvallely.com The Aware Mind on Instagram https://www.instagram.com/aware_mind_podcast/TSD Mindfulness Virtual Meditation Center http://www.tsdmind.org Jacob's Personal Training website http://www.jacobderossett.com Jacob's YouTube Channel https://tinyurl.com/9yykwne9This episode is a meditation for beginners, and mindfulness for beginners resource. Intermediate and advanced meditators will also benefit. The Aware Mind produces content that supports stress reduction, anxiety relief, better concentration and focus, and trauma healing.The Aware Mind is produced by TSD Mindfulness, a virtual meditation center, offering mindfulness classes, certifications and private coaching. Sponsorded by RENVA Turmeric Shakes

An episode that defies the norms.Here's what's in store for today's episode: * Today, hosts Matt and Angela explore the intriguing and often debated world of Pathological Demand Avoidance with special guest Richard Woods.* Pathological Demand Avoidance, also known in more affirming circles as Persistent Drive for Autonomy, describes a strong need to question and resist demands, often co-occurring with autism. This trait can manifest as an intense drive for control, leading individuals to navigate the world in ways that prioritize autonomy and flexibility over compliance.* Most of what we know about PDA autism—and the stereotypes surrounding it—are heavily focused on children. In reality, PDA exists on a spectrum, and many adults also experience its traits, often in ways that go unrecognized or misunderstood.* Many neurotypicals see PDA as indistinguishable from Oppositional Defiant Disorder (ODD), when in reality, PDA is often the underlying factor in these cases, driven by a need for autonomy rather than intentional defiance.* We explore the validity of Theory of Mind in relation to PDA and the problems with pathologizing demand avoidance.* Our hosts and special guest discuss the misconception that PDA traits fade with age—when in reality, PDA individuals learn to accommodate themselves and establish clear boundaries as they grow into adulthood.* We explore the overlap between PDA and ODD, and why Richard believes that PDA isn't a form of autism, but rather a distinct profile of neurodivergence.* Additionally, we discuss how neurotypicals often struggle to differentiate CPTSD symptoms from autism, as many have never encountered a healthy, healed autistic person.* The discussion then shifts to how the world is not designed for autistic or disabled people in general, and how this lack of accessibility and understanding can exacerbate PDA traits, making self-advocacy and autonomy even more crucial.* We talk about labels, how they affect our ability to get our needs met, and what Richard's "post-autistic identity" entails in the broader conversation around neurodivergence and self-definition.* Finally, we reflect on the importance of self-advocacy, community, and embracing neurodivergence beyond medical labels, as well as the role of monotropic focus in the autistic experience.“May your stimming activities be many, and your flow states long.” About Richard Woods:Richard Woods is the leading Demand Avoidance Phenomena (Pathological Demand Avoidance) authority (by academic work and experience) and Author.He is attributed as autistic, but has a "post-autistic identity" as he is no longer basing his identity on psychiatric categories.“I tend to view PDA as literally about the management of stress. A lot of people express these features because they are distressed and or stressed by the demands being placed upon them. And often with autistic people, it seems to be more of a cognitive style. We're to be stressed when you put us in a very chaotic, very high-demanding world.” - Richard Woods“The modern life isn't built for autistics. It's so much noise, so much sound, so much that is visual and tactile. It's not built for disabled people in general.” - Richard Woods “That's the thing [about autistic kids] - when we have a safe person, when we have that anchor person, it frees us to be more objective, or to object rather, because it's safer to object. As opposed to a total stranger, you may not feel safe saying, ‘no, I don't want to do that. But with someone you trust, you say, ‘no, there's no way I'm going in there. You can't make me do that.' That's not going to happen, because you know you're not going to be met with that judgment and the criticism that comes along with that of a stranger.” - Matt In this episode, we take a deep dive into the world of Pathological Demand Avoidance (PDA) autism, a lesser-known but important part of the spectrum. From the intense need for autonomy to the challenges of navigating a demand-heavy world, we explore what PDA really is—and what it isn't. Join Matt and Angela as they break down common misconceptions, discuss how PDA presents in adults, and chat with expert Richard Woods about the affirming perspective of Persistent Drive for Autonomy. Have you experienced PDA traits in yourself or others? Share your thoughts with us using #AutisticCultureCatch on social media!Show Notes:There is substantial debate over what PDA is. Presently my view PDA is not an "autism profile"/ autism subgroup/ autism subtype, or anything of the kind. For a short 800 word overview of current debates on PDAby Richard Woods, please see below:https://www.researchgate.net/publication/354386742_Pathological_demand_avoidance_PDA_Its_four_schools_of_thoughthttps://tinyurl.com/4wynmydzRichard Woods ORCiD: https://orcid.org/0000-0002-8292-632Xhttps://www.pdasociety.org.uk/resources/identifying-features-ofpathological-demand-avoidance-using-the-diagnostic-interview-forsocial-andcommunication-disorders/https://monotropism.org/dinah/https://dlcincluded.github.io/MQ/Pathological Demand-Avoidance" (PDA) in Frontiers in Education, please see the call for papers below for more information:http://fron.tiers.in/rt/40032Related Shows:Reframing DSM Diagnosis Ready for a paradigm shift that empowers Autistics? Help spread the news!Follow us on InstagramFind us on Apple Podcasts and SpotifyLearn more about Matt at Matt Lowry, LPPJoin Matt's Autistic Connections Facebook GroupLearn more about Angela at AngelaKingdon.com Angela's social media: Twitter and TikTokOur Autism-affirming merch shop This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.autisticculturepodcast.com/subscribe

In this episode, we detail the gut's intricate immune defenses, emphasizing the role of mast cells in inflammation and immune signaling. We extend this conversation to Mast Cell Activation Syndrome briefly going through potential triggers, tests, and symptoms. Finally, we examine the bidirectional relationship between MCAS and Small Intestinal Bacterial Overgrowth (SIBO), illustrating how mast cell mediators and microbial byproducts can drive a cycle of chronic inflammation and increased intestinal permeability. Topics: 1. Introduction to the Gut-Immune Axis - Focus: mast cells, small intestinal bacterial overgrowth (SIBO), and mast cell activation syndrome (MCAS). 2. Anatomy of the Gastrointestinal Lining - Intestinal lumen, microbiome, mucus layer, epithelial monolayer, tight junctions, and lamina propria. - Role of the smooth muscle and deeper layers supporting the mucosal structures. 3. Gut-Associated Lymphoid Tissue (GALT) - Peyer's patches, mesenteric lymph nodes (MLNs), isolated lymphoid follicles (ILFs), intraepithelial lymphocytes (IELs), and dispersed immune cells in the lamina propria. - Function of GALT. 4. Peyer's Patches and Antigen Exposure - Location and function of Peyer's patches. - Role in antigen sampling and processing. 5. Immune Cells in the Lamina Propria - Overview of interspersed immune cell populations. 6. Focus on Mast Cells - Key roles of mast cells in the gut's innate immune system. - Locations with a focus on the lamina propria. 7. Mast Cell Mediators - Histamine - Tryptase: tissue remodeling, impact on intestinal permeability. - Cytokines, prostaglandins, and leukotrienes. 8. Mast Cell Activation Syndrome (MCAS) - Overactivation of mast cells and excessive release of inflammatory mediators. - Effects on gut barrier function. - Pathological behavior due to altered activation thresholds, receptor expression, and tissue environment changes (not resulting from an increased number of mast cells). 9. MCAS Symptoms and Systemic Effects - Abdominal pain, cramping, bloating, diarrhea, and nausea. - Systemic symptoms: skin reactions, respiratory and cardiovascular effects, neurological impacts. 10. Triggers and Conditions Associated with MCAS - Environmental toxins, infections, stress, chemical exposures. - Hypermobile Ehlers-Danlos syndrome (hEDS), dysautonomia (e.g., POTS). 11. MCAS Testing - Testing limitations: variability in mediator release and transient nature of mast cell degranulation. - Serum tryptase, urinary N-methylhistamine, plasma heparin levels, specific cytokines like IL-6, and more. 12. Small Intestinal Bacterial Overgrowth (SIBO) - Overview of SIBO. - Slow motility, low stomach acid. 13. Interaction Between SIBO and Mast Cells - SIBO-induced mast cell activation. - Cycle of inflammation, increased intestinal permeability, and gut dysfunction. 14. Conclusion - Recap of the intestinal anatomy and immune cell focus. - MCAS triggers, symptoms, and testing. - Connections between SIBO and MCAS, emphasizing an inflammatory cycle. Thank you to our episode sponsor: 1. Check out ⁠⁠⁠Ulyana Organics'⁠⁠⁠ ⁠⁠⁠Tallow Wild Yam Cream⁠⁠⁠ and ⁠⁠⁠Healing Facial Oil⁠⁠⁠, and use code ⁠⁠⁠CHLOE10⁠⁠⁠ 10% off your order. Thanks for tuning in! Get Chloe's Book Today! "⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠75 Gut-Healing Strategies & Biohacks⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠" Follow Chloe on Instagram ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@synthesisofwellness⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Follow Chloe on TikTok @chloe_c_porter Visit ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠synthesisofwellness.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ to purchase products, subscribe to our mailing list, and more!

BUFFALO, NY- January 14, 2025 – A new #research paper was #published in Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science) Volume 16, Issue 22 on November 26, 2024, entitled “When do the pathological signs become evident? Study of human mesenchymal stem cells in MDPL syndrome.” Researchers from the University of Rome Tor Vergata, Fondazione Policlinico Tor Vergata, Roma Tre University, and Meyer Children's Hospital IRCCS have identified early cellular changes associated with Mandibular Hypoplasia, Deafness, Progeroid Features, and Lipodystrophy (MDPL) syndrome, a rare genetic aging disorder caused by a mutation in the POLD1 gene. MDPL leads to fat loss, distinct facial features, and metabolic disturbances. This study aimed to better understand how MDPL progresses at the cellular level. MDPL syndrome is extremely rare, with only a few documented cases worldwide, making it difficult to study. To investigate the disease, researchers Spitalieri Paola, Guerrieri Lara, Murdocca Michela, Di Cesare Silvia, Maccaroni Serena, Pecorari Rosalba, Nardone Anna Maria, Candi Eleonora, Colasuonno Fiorella, Gori Giulia, Traficante Giovanna, Novelli Giuseppe, and Sangiuolo Federica, converted skin cells from three female MDPL patients and two healthy donors into human induced pluripotent stem cells (hiPSCs). These hiPSCs were then transformed into mesenchymal stem cells (MSCs), cells that can form tissues like bone and fat, which are primarily affected in MDPL syndrome. The study revealed that MSCs from MDPL patients exhibited signs of premature aging much earlier than expected. The cells had irregular shapes, grew at a slower rate, and showed higher levels of cellular stress. “These cells differentiate with lower efficiency, proliferate more slowly and have abnormal mitochondrial activity with increased production of ROS. Furthermore, the telomeres show evident shortening.” All the findings suggest that aging-related changes may occur long before patients display visible symptoms of the disease. This highlights the need for early diagnosis and intervention, which could delay or even prevent the most debilitating effects of MDPL syndrome. In summary, this study offers new perspectives on the initial cellular impacts of MDPL, opening the door for the creation of novel treatments. The findings highlight the potential for personalized therapies and emphasize the critical role of lab-created hiPSCs in advancing research on rare genetic diseases and age-related conditions. DOI - https://doi.org/10.18632/aging.206159 Corresponding author - Sangiuolo Federica - sangiuolo@med.uniroma2.it Video short - https://www.youtube.com/watch?v=DLXD2ztPTm0 Sign up for free Altmetric alerts about this article - https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.206159 Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts Keywords - aging, MDPL syndrome, MSCs, hiPSCs, POLD1 gene About Aging-US The mission of the journal is to understand the mechanisms surrounding aging and age-related diseases, including cancer as the main cause of death in the modern aged population. The journal aims to promote 1) treatment of age-related diseases by slowing down aging, 2) validation of anti-aging drugs by treating age-related diseases, and 3) prevention of cancer by inhibiting aging. (Cancer and COVID-19 are age-related diseases.) Please visit our website at https://www.Aging-US.com​​ and connect with us: Facebook - https://www.facebook.com/AgingUS/ X - https://twitter.com/AgingJrnl Instagram - https://www.instagram.com/agingjrnl/ YouTube - https://www.youtube.com/@AgingJournal LinkedIn - https://www.linkedin.com/company/aging/ Pinterest - https://www.pinterest.com/AgingUS/ Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc MEDIA@IMPACTJOURNALS.COM

In this episode I go over a section of one of my favorite books in the areas of dog training.

Dan Slepian is an Emmy-winning journalist, producer, and storyteller with nearly 30 years at NBC News. Known for his investigative work on Dateline, Dan has exposed injustices, solved cold cases, and helped exonerate the wrongfully convicted. His acclaimed podcast, Letters from Sing Sing, chronicles his 20-year fight to prove the innocence of John Adrian “JJ” Velazquez. A 2024 Pulitzer Prize finalist, Dan recently published The Sing Sing Files: One Journalist, Six Innocent Men, and a 20-Year Fight for Justice. Beyond journalism, he is a passionate advocate for criminal justice reform, focusing on the human cost of mass incarceration.In this episode, Dan discusses the systemic flaws in the justice system, including racial bias, prosecutorial misconduct, and the lack of accountability for wrongful convictions. He brings a deeply personal and professional lens to the conversation, emphasizing his commitment to truth over personal recognition. He shares insights into the realities of mass incarceration, describing how systemic failures—from flawed eyewitness procedures to prosecutorial pressure—lead to wrongful convictions. Dan also explores his relationship with JJ, which has evolved into a profound bond that underscores the human toll of these injustices. He speaks candidly about his investigative process, the importance of humanity and empathy, and his enduring advocacy for those wrongly imprisoned. His accounts of JJ's case and his Voices from Within program highlight the potential for transformation and healing within and beyond prison walls. Dan dives into his recent book, The Sing Sing Files, and the forthcoming documentary series The Sing Sing Chronicles, which humanizes those affected by the system. Dan's Reluctance Toward Self-Promotion: Dan discusses his discomfort with being in the spotlight + he reflects on the challenges of public advocacy while maintaining journalistic objectivity (3:26)Upbringing and Family Influence: Dan shares his childhood experiences + He credits his mother for instilling grit and resilience and his father for teaching empathy and the value of fighting for others (6:37)Navigating Advocacy and Family Dynamics: Dan recounts the depth of his 20-year connection with JJ + how Dan's work evolved from investigative reporting into a deeply personal mission for truth + how Dan's family became an integral supporter of JJ (9:52)Journey into Journalism: Dan recounts the early days of his career + He shares formative moments, like witnessing Michael Jordan before a game and the lessons they imparted about professionalism. (19:11)The Case of Robert Roberson: Robert Roberson's case, a man on death row convicted of killing his daughter + science have debunked much of the evidence used against Roberson + Dan emphasizes the racial and procedural inequities in death penalty cases and critiques the system's inefficiencies, high costs, and lack of deterrence (22:20)The Roots of Wrongful Convictions: Systemic issues leading to wrongful convictions + eyewitness misidentification, coerced confessions, and improper courtroom dynamics + JJ Velazquez's case exemplifies these failures + the need to humanize those impacted by wrongful convictions (34:53)Voices from Within and JJ Velazquez's Journey: Systemic bias in the justice system, , pointing out how former prosecutors often become judges in the same jurisdictions, fostering a “club-like” atmosphere + Dan's and JJ's collaboration on Voices from Within + challenging myths like “everyone in prison claims innocence + the long-lasting trauma caused by wrongful incarceration (45:00)The Emotional Catalyst for Justice: the emotional impact of his first encounter with JJ's children + Dan developed a familial bond with JJ's children + the lifelong impact of losing a parent to incarceration (51:56)The Pathology of Mass Incarceration: The Sing Sing Files, and the emotional impact of the documentary series The Sing Sing Chronicles + education and vocational training in prisons + need to treat prisoners with dignity and reintegrate them into society + mass incarceration as a moral failing of society (55:02)The Innocence Project and Personal Reflections: Dan credits the Innocence Project + Dan maintains his discomfort with being labeled as a trailblazer (1:111:07)Rapid Fast Round (1:12:46) Connect with Dan Slepian:InstagramLinkedInGet Dan's book - The Sing Sing Files!Listen to Dan's podcast - Letters from Sing Sing! Let's talk Connect:Instagram This podcast is produced by Ginni Media.

How to know that you're dealing with a toxic person? They do exist, and chances are we've met one or 2. Sometimes they might not realize they're causing harm to others. There are situations that might be putting us at risk and, without us knowing it, damaging our sense of worth. Fortunately, there are warning signs you can look for to see if the person you're dealing with is a toxic person. #toxicpeople #toxicrelationship # TIMESTAMPS: Toxic people play the victim 1:02 Emotional abuse 2:52 Pathological liars 4:07 Toxic people seek to control 5:25 People who don't respect boundaries 6:32 Negative people 7:59 Music: https://www.youtube.com/audiolibrary/... SUMMARY People who struggle with the victim mentality don't think they have power over their lives, and they blame other people and circumstances for how unhappy they are. They also avoid responsibility. Have you ever been in a situation where you believed someone owed you an apology but, by the end of the conversation, you ended up apologizing instead? That is a classic victim attitude, in which they flip the situation. Emotional abuse can be one of the most painful forms of violence and a killer of self-esteem. It can be verbal: yelling, belittling, criticism, and accusing. It can also be subtle: intimidation, manipulation, and the “silent treatment.” Pathological liars take lying to the extreme. A pathological liar is someone who constantly tells lies, usually in an effort to protect their image. They are masters of manipulation and can lie straight to your face. They tend to be impulsive people with a deep need to impress. Their lies might not always have a purpose, and sometimes they might lie to you just because they can. Some toxic people can be master manipulators, and they are clever about hiding their true intentions. Controlling people might want to know where you are and who you are with. They might be vocal about it or try to control you in more subtle ways. Toxic people project their vulnerabilities and insecurities onto another person in the form of anger and bullying. They are incapable of respecting boundaries. They can't process their own toxicity, so they deal with it by putting it onto someone else. Everyone can feel negative sometimes. But toxic people wish to share their negativity with the world, and it can spread like wildfire. They can only speak of bad news or negative stories and complain nonstop. Subscribe to Bright Side : https://goo.gl/rQTJZz ---------------------------------------------------------------------------------------- Our Social Media: Facebook:   / brightside   Instagram:   / brightgram   5-Minute Crafts Youtube: https://www.goo.gl/8JVmuC ---------------------------------------------------------------------------------------- For more videos and articles visit: http://www.brightside.me/ Learn more about your ad choices. Visit megaphone.fm/adchoices

[SEGMENT 1-1] The Science of Lying 1   https://www.youtube.com/watch?v=MX3Hu8loXTE – The Science of Lying; I used some of this in the radio show that I'm doing about this subject. I will make those audio clip available to you, but I will need to rewrite this and cut it on video.   My story of my father.   [X] SB – Lying Clip 2 – Learning to lie   Lying. Nobody teaches you how to lie.  [SEGMENT 1-2] The Science of Lying 2     [X] SB – The Science of Lying – Clip 1 Humans are social animals Lying keeps elaborate social structures running smoothly while looking out for #1   I have a friend and I called him late one evening. He was obviously sleeping, but he answered my call. I asked him, “Did I catch you sleeping?” And he was obviously groggy, but answered “No.” I knew he was lying, but he didn't want me to feel bad for waking him up, so he lied. I felt good knowing that he respected me enough to lie to me. But I tried not to call him again at that time.   It really is a natural thing.    [SEGMENT 1-3] The Science of Lying 3   Long past my lying stage. Took longer than it should have. I was relaying a story about getting put on a plan. 400% of quota. Difficult to work with. Not bendable. Amazing year   And as we grow, our lies grow. It's the nature of a lie. It will get bigger if left unchecked. A teenager lies about where he or she is, at least before they were tracked on smart phones. Maybe you damaged the car, but you hid it and hoped your parents wouldn't notice for a bit, and nobody would know where the damage came from.   [X] SB – Lying Clip 3 – Pathological lying Lying not ok. We're good at it We are so good, we do it to ourselves. Pathological liars: super good at self-deception Wholeheartedly believe their own lies Difference between pathological liars and regular people.   [X] SB – Biden at the G7 American people aren't satisfied  [SEGMENT 1-4] The Science of Lying 4   [INSERT: something where a teenager lies…Superbad] from beginning to 0:39   Again, as the issues grow, the lies grow bigger. Why? Because the consequences of the truth could be devastating. For example, if you get caught cheating, it could ruin your marriage. So the first reaction for most is to lie when caught. You might lie in that situation to cover your butt. And some may rationalize that lie as “protection for the persons being cheated on”.   [INSERT: something where a person is covering up cheating…Woman in Red]   If you get caught in enough lies, you might decide that lying is not the best course of action. You develop a conscience; a moral guideline. If you're smart, you do your best not to lie. You face the consequences of your actions. That's called adulthood. In the sane world, parents teach children to stop lying. This is done by showing that lying is not good. In this scene from The Hangover, the dentists lies to his wife, because he's been emasculated.   [MOVIE SCENE from the Hangover where the dentist lies to his wife]; from 0:48 to 1:42]   As we learn, his lying underlies the real problem. He's in a bad marriage. One where the truth exposes that fact.   [MOVIE SCENE in The Hangover where he confronts his wife]; [from beginning to 1:31]  Become a supporter of this podcast: https://www.spreaker.com/podcast/the-kevin-jackson-show--2896352/support.

Dr. Rebecca Wattam is a Research Associate Professor in the Network Dynamics and Simulation Science Laboratory within the Biocomplexity Institute of Virginia Tech. Rebecca is the outreach and biology lead for a bioinformatics research center that scientists use to share and analyze their data on bacteria and bacterial genomes. This research center was originally funded to study bacteria that can make us sick in order to develop vaccines, identify drug targets, and predict outbreaks of illnesses. However, there are a lot of beneficial types of bacterial that are also now being studied based on their use for fermentation, alternate energy sources, probiotics, and other purposes. Rebecca is particularly interested in examining the similarities and differences between groups of bacteria. Living in Blacksburg, Virginia, Rebecca is close to the beautiful Appalachian Trail. She spends much of her free time hiking, canoeing, exploring the outdoors, and watching the wildlife. Rebecca received her B.S. and M.S. degrees from the University of New Mexico in Biology. Next, she attended the University of Wisconsin-Madison where she earned a joint Ph.D. degree in Entomology and Veterinary Science. Rebecca received a MacArthur Fellowship to conduct postdoctoral research at the University of Arizona in Tucson, and she completed a second postdoctoral fellowship there as well before accepting a position on the faculty at Virginia Tech. In our interview, Rebecca speaks more about her experiences in life and science.

In this episode, Dr. David Puder, alongside experts Anthony Bateman, Dr. Brandon Unruh, and Robert Drozek, delves into the complexities of treating pathological narcissism with Mentalization-Based Therapy (MBT). They explore practical strategies to help individuals with Narcissistic Personality Disorder develop self-awareness, emotional regulation, and healthier relationships. Learn how MBT can transform the therapeutic journey for those who often feel misunderstood or resistant to change. 

Pathological loneliness is a state of deep, persistent loneliness and feelings of worthlessness that can be considered a disease. It can be a major problem in older adults and is associated with an increased risk of developing biological dysfunctions, psychological distress, and behavioral problems.

Season Four Back To School Series Episode 2 - Science Class The Neuroscience of Mediumship Today, we're continuing our "Back to School" Series with a visit to Science class and the Neuroscience of Mediumship! In this special episode, we dive deep into the fascinating intersection of neuroscience and spirituality with Kaylee, a neuroscience student from Barnard University. Introduced to me by her aunt, medium and life coach Mary Beth Thomsen, Kaylee shares groundbreaking research that explores the links between auditory hallucinations in mediums and clinical conditions like schizophrenia. Joined by guest host Brooke Carey, we explore how spiritual experiences and clinical hallucinations may be more closely connected than we realize. From culture and selective attention to the potential therapeutic applications of her findings, this conversation shines a light on the innovative frontiers of brain research. Tune in as we unravel the science behind hearing from Spirit and how neuroscience is beginning to unlock the mysteries of mediumship. Show Notes: 00:00 Exciting Introduction to a Special Episode 02:11 Meet Kaylee: A Brilliant Young Scientist 02:37 Kaylee's Journey into Mediumship 05:01 Discovering Neuroscience and Personal Motivations 06:42 The Fascinating Research on Hallucinations 09:21 Understanding Mediumship and Hallucinations 16:06 Exploring Cultural and Clinical Perspectives 25:17 Kaylee's Research Methods and Findings 26:42 Exploring Absorption and Mental Imagery 27:52 Understanding Dissociation and Absorption 28:28 Pathological vs. Non-Pathological Dissociation 31:23 Mediumship and the Brazilian Kardecism Mediums 36:12 Top-Down Processing and Hallucinations 41:57 Neurobiological Correlates of Mediumship 47:24 Future Research and Applications 50:36 Concluding Thoughts If you would like to read Kaylee's paper or want to hear more from Kaylee, please email her directly at kat2205@barnard.edu Connect with Emily Website: https://www.emilyandherstars.com Classes and Bookings: https://www.emilyandherstars.com Newsletter + Calendar Download: https://view.flodesk.com/pages/60f5b4f9a00fcd52c9f65d4b

Jessica Lewis, PT, DPT, PCS, is on the show again for this two part discussion on pathological gait with Sara and Sheila. Jessica is one of the co-creators of PCS Advantage, currently working on her PhD, and works in a gait and motion analysis lab at a children's hospital in Ohio. If you have not listened to part 1 of our conversation, please go back and listen to Season 4 Episode 8. Today is part two, the continuation of our discussion on pathological gait in the pediatric population.  “The Toe Walking Tool: A novel method for assessing idiopathic toe walking children” Gait Patterns Reference Photo 1 Gait Patterns Reference Photo 2 Check out PCS Advantage   Primary resources can be found on our website Use code PUSHING PEDS for $150 off your Medbridge subscription!  Check out our website, and subscribe for our subscription only episodes Follow us on Instagram This episode was brought to you by the Pivot Ball Change Network.

The Joker from the Batman universe is undoubtedly one of the most fascinating characters ever created. He's been reimagined countless times, not only in comics but also in video games, TV shows, and films. It's definitely no exaggeration to say he's become a staple of pop culture! In the Trecent Todd Phillips movie, we get to know a lot more about Arthur Fleck, a man who suffers from a condition that causes uncontrollable laughing fits, that are so intense that they unsettle everyone around him. Phoenix's portrayal earned him both an Oscar and a Golden Globe. Can people really laugh in such an uncontrollable way? Why can't they stop then? In under 3 minutes, we answer your questions! To listen to the last episodes, you can click here: Which are the best cities in the world to live in? How can I influence my dreams? What are umbrella species? A podcast written and realised by Joseph Chance. Learn more about your ad choices. Visit megaphone.fm/adchoices

Jessica Lewis, PT, DPT, PCS, is back on the show for this two part discussion on pathological gait with Sara and Sheila. Jessica is one of the co-creators of PCS Advantage, currently working on her PhD, and works in a gait and motion analysis lab at a children's hospital in Ohio. In today's part one we will cover normal gait development and then start dissecting the different types of pathological gaits. Come back next week for part two of this discussion! “The Toe Walking Tool: A novel method for assessing idiopathic toe walking children” Gait Patterns Reference Photo 1 Gait Patterns Reference Photo 2   Resources discussed in today's episode can be found on our website Use code PUSHING PEDS for $150 off your Medbridge subscription!  Check out our website, and subscribe for our subscription only episodes Follow us on InstagramThis episode was brought to you by the Pivot Ball Change Network.

Diana N. Ionescu, MD - Pathological Assessment of HER2 Status in Gastric and Gastroesophageal Cancers: Important Steps That Can Impact Outcomes

Diana N. Ionescu, MD - Pathological Assessment of HER2 Status in Gastric and Gastroesophageal Cancers: Important Steps That Can Impact Outcomes

Today, a conversation all about conceptual art with the conceptual artist, essayist, and AI dilettante/explorer, Kevin Esherick. Having tackled dense conceptual topics in AI, generative aesthetics, things relating to life and the self and the spirit alike, Kevin is the perfect person to discuss making conceptual art communicable online, the way inspiration affixes itself to a certain medium, ambition, effort, AI, and his latest project, I'm With You, releasing soon.    Find Kevin here: https://x.com/kev_esh And learn more about I'm With You here:  https://x.com/kev_esh/status/1838950210669580396 https://verse.works/series/im-with-you-by-kevin-esherick  

On this episode of Chasing Leviathan, PJ and Dr. Nima Bassiri discuss the intersection of psychiatry and capitalism. Dr. Bassiri argues that the concept of 'pathological value' is central to understanding this intersection, as it refers to the economic worth conferred upon madness. Dr. Bassiri traces the history of madness and capitalism, highlighting how certain forms of pathology can be seen as assets, particularly in the context of entrepreneurship. Through the conversation, Dr. Bassiri calls attention to the troubling dominance of economic discourse in defining success and evaluating human conduct.For a deep dive into Nima Bassiri's work, check out his book: Madness and Enterprise: Psychiatry, Economic Reason, and the Emergence of Pathological Value

Do you find yourself constantly putting others' needs before your own? Have you ever wondered if being "too kind" could actually be harmful to your relationships and well-being? In today's crossover episode - Tony Overbay, a licensed marriage and family therapist, explores the complex concept of pathological kindness in relationships. Through a listener's letter from 'Cleo,' Tony delves into the challenges faced by those who prioritize others' needs to their detriment, often rooted in childhood experiences of being the family peacemaker. Cleo's story highlights issues with her emotionally inconsistent partner, Ray, unveiling the struggles of living with someone emotionally immature or narcissistic. Tony discusses recognizing these patterns, including the role of cognitive dissonance and trauma bonding in maintaining unhealthy relationships. He explores how highly sensitive people (HSPs) may be particularly vulnerable to these dynamics. The episode emphasizes the importance of developing a stable core identity, setting boundaries, and balancing kindness with self-care. Tony also touches on the challenges of breaking free from intermittent reinforcement in relationships and recognizing and trusting one's own perceptions. He stresses the role of therapy and self-awareness in breaking free from unhealthy cycles and fostering emotionally mature relationships while also offering hope to those who recognize themselves as the emotionally immature partner and want to change. 00:00 Introduction and Podcast Promotion 01:19 Introducing Cleo's Story 03:16 Cleo's Relationship Struggles 10:38 Understanding Pathological Kindness 16:28 The Impact of Pathological Kindness 21:36 Balancing Kindness and Self-Care 25:09 Exploring Self-Reliance and Its Pitfalls 25:24 The Dual Nature of Optimism 25:40 Understanding Humility and Self-Deprecation 26:26 The Complexities of Honesty 27:09 Patience vs. Passivity 27:24 Competence and Arrogance 28:00 Cleo's Relationship with Ray 29:04 The Struggle of Highly Sensitive People 29:48 The Challenge of Leaving Toxic Relationships 33:23 The Cognitive Dissonance and Trauma Bonding 45:04 The Importance of Self-Care and Boundaries 46:03 Encouragement for Personal Growth To learn more about Tony's upcoming re-release of the Magnetic Marriage course, his Pathback Recovery course, and more, sign up for his newsletter through the link at https://linktr.ee/virtualcouch Available NOW: Tony's "Magnetic Marriage Mini-Course" is only $25. https://magneticmarriage.mykajabi.com/magnetic-marriage-mini-course Subscribe to Tony's latest podcast, "Waking Up to Narcissism Q&A - Premium Podcast," on the Apple Podcast App. https://podcasts.apple.com/us/podcast/waking-up-to-narcissism-q-a/id1667287384 Go to http://tonyoverbay.com/workshop to sign up for Tony's "Magnetize Your Marriage" virtual workshop. The cost is only $19, and you'll learn the top 3 things you can do NOW to create a Magnetic Marriage. You can learn more about Tony's pornography recovery program, The Path Back, by visiting http://pathbackrecovery.com And visit Tony mentioned a product that he used to take out all of the "uh's" and "um's" that, in his words, "must be created by wizards and magic!" because it's that g

Do you find yourself constantly putting others' needs before your own? Have you ever wondered if being "too kind" could actually be harmful to your relationships and well-being? In today's crossover episode - Tony Overbay, a licensed marriage and family therapist, explores the complex concept of pathological kindness in relationships. Through a listener's letter from 'Cleo,' Tony delves into the challenges faced by those who prioritize others' needs to their detriment, often rooted in childhood experiences of being the family peacemaker. Cleo's story highlights issues with her emotionally inconsistent partner, Ray, unveiling the struggles of living with someone emotionally immature or narcissistic. Tony discusses recognizing these patterns, including the role of cognitive dissonance and trauma bonding in maintaining unhealthy relationships. He explores how highly sensitive people (HSPs) may be particularly vulnerable to these dynamics. The episode emphasizes the importance of developing a stable core identity, setting boundaries, and balancing kindness with self-care. Tony also touches on the challenges of breaking free from intermittent reinforcement in relationships and recognizing and trusting one's own perceptions. He stresses the role of therapy and self-awareness in breaking free from unhealthy cycles and fostering emotionally mature relationships while also offering hope to those who recognize themselves as the emotionally immature partner and want to change. 00:00 Introduction and Podcast Promotion 01:19 Introducing Cleo's Story 03:16 Cleo's Relationship Struggles 10:38 Understanding Pathological Kindness 16:28 The Impact of Pathological Kindness 21:36 Balancing Kindness and Self-Care 25:09 Exploring Self-Reliance and Its Pitfalls 25:24 The Dual Nature of Optimism 25:40 Understanding Humility and Self-Deprecation 26:26 The Complexities of Honesty 27:09 Patience vs. Passivity 27:24 Competence and Arrogance 28:00 Cleo's Relationship with Ray 29:04 The Struggle of Highly Sensitive People 29:48 The Challenge of Leaving Toxic Relationships 33:23 The Cognitive Dissonance and Trauma Bonding 45:04 The Importance of Self-Care and Boundaries 46:03 Encouragement for Personal Growth If you are interested in joining Tony's private Facebook group for women in narcissistic or emotionally immature relationships of any type, please reach out to him at contact@tonyoverbay.com or through the form on the website, https://www.tonyoverbay.com If you are a man interested in joining Tony's "Emotional Architects" group to learn how to better navigate your relationship with a narcissistic or emotionally immature partner or learn how to become more emotionally mature yourself, please reach out to Tony at contact@tonyoverbay.com or through the form on the website, https://www.tonyoverbay.com

Ever find yourself drawn to the same type of partner, even when those relationships prove unhealthy or toxic or abusive?  After suffering from a series of toxic relationships with narcissistic partners, Ross Rosenberg embarked on a journey to understand the roots of codependency and self-love deficiency. His quest led him to develop the comprehensive Self-Love Recovery Treatment Program, which is transforming the way therapists and individuals approach healing from codependency. In this episode, Ross Rosenberg joins Dr. Wendy Myers to expose the hidden forces of codependency, a condition he reframes as "self-love deficit," and its potent attraction to narcissism.  Ross unravels the mystery of why we repeatedly choose partners who are incapable of meeting our needs. He illuminates how these patterns often stem from early childhood experiences, creating a subconscious blueprint for seeking out narcissistic individuals. Discover the science behind this magnetic pull and how to break free from its grip. Ross introduces his new book, The Codependency Revolution, a transformative guide packed with educational resources and practical steps to help you break free from codependency and embark on a powerful healing journey.   "The only way to solve self-love deficit or codependency is to first know what it is" ~ Ross Rosenberg   Today's Episode Explores: - Ross's new book: The Codependency Revolution - Defining codependency/self-love deficit disorder - Why it will need a revolution to treat codependency - How does one become codependent? - How to identify and avoid narcissists - Symptoms of self-love deficit - Pathological loneliness and how it affects the codependents - The Addiction cycle in codependency - Challenges in identifying narcissists - Effective treatment solutions for codependency - The importance of trauma-informed therapy - Strategies for leaving a narcissistic relationship - How narcissists react when a codependent starts healing For more information, visit www.myersdetox.com    Is fatigue ruining your life? Take Dr. Wendy Myers' free quiz to discover how to fix it with detox! www.heavymetalsquiz.com    Products & Resources Mentioned: - The Codependency Revolution - https://a.co/d/cIgZpgT  - The Human Magnet Syndrome - https://a.co/d/292KQIl  - pH Prescription Water Filters - Take control of your water quality and schedule a free consultation with the "Water Doctors" today by calling 772-220-8789 or visiting their website at phprescription.com.  - Pure Body Extra Zeolite - Start living a healthier life and order your bottle now at thegoodinside.com.   About Ross Rosenberg: Ross Rosenberg is a renowned psychotherapist, author, and codependency expert who has dedicated his career to understanding and treating self-love deficit disorder. With over 30 years of experience in the mental health field, Ross has developed a revolutionary approach to helping individuals break free from the cycle of codependency and narcissistic abuse. His bestselling books, including "The Human Magnet Syndrome" and "The Codependency Cure," have sold over 135,000 copies and have been translated into nine languages. Ross's passion for empowering individuals to cultivate authentic self-love and build healthy relationships has made him a sought-after speaker and a trusted authority in the field of codependency recovery.  Visit Selfloverecovery.com today to learn more about Ross's work and to find the tools you need to overcome codependency and cultivate authentic self-love.   Disclaimer The Myers Detox Podcast was created and hosted by Dr. Wendy Myers. This podcast is for information purposes only. Statements and views expressed on this podcast are not medical advice. This podcast, including Wendy Myers and the producers, disclaims responsibility for any possible adverse effects from using the information contained herein. The opinions of guests are their own, and this podcast does not endorse or accept responsibility for statements made by guests. This podcast does not make any representations or warranties about guests' qualifications or credibility. Individuals on this podcast may have a direct or indirect financial interest in products or services referred to herein. If you think you have a medical problem, consult a licensed physician.

Atari 8 bit computers Atari ST RM Nimbus Dark Conspiracy Autism Local Exchange Trading Systems PowerBook

We literally cannot stop talking about Couples Therapy. Thankfully, Johnny segues into Below Deck and Captain Lee's aphorisms, having it your way, dealing with the head of HR, changing your name to Arbys and being a singer, putting condoms on fruits, and more. PLUGS! Get everything ManDog at The Patreon! Check out Alison's short Pathological! Check out Johnny's movie Papa Wingo and his improv team Sentimental Lady! Subscribe to ⁠⁠ManDog on YouTube! Check out ⁠⁠BigGrandeWebsite.com⁠⁠! Subscribe to ⁠⁠Big Grande⁠⁠ on Youtube! Subscribe to Yes, Also! Subscribe to The Greatest Conversation Ever on YouTube! Or Join the VIP! Subscribe to Hey Randy and Bill Walton Podcast on www.comedybangbangworld.com/

The Power of Now - A Guide to Spiritual Enlightenment with Gilda and Barbara In this episode, we cover "A New Earth - Chapter 4, Section 16 Role-Playing: The Many Faces of the Ego - Pathological Forms of Ego" by Eckhart Tolle Gilda Simonet and Barbara Wainwright have been studying Eckhart Tolle's work for ages. For the podcast purposes, we plan to go through the book from start to finish, reading only one section at a time. There are 122 sections of the book! Join our Facebook Group "The Power of Now - A Guide to Spiritual Enlightenment with Gilda and Barbara" https://www.facebook.com/groups/thepowerofnowaguidetospiritualenlightmentwithgandb/ Contribute to our show here: https://podcasters.spotify.com/pod/show/barbara-wainwright/support Learn more about Barbara Wainwright and our Coaching Courses here: http://www.LifeCoachTrainingOnline.com 800-711-4346 --- Support this podcast: https://podcasters.spotify.com/pod/show/barbara-wainwright/support

Why do Ontario winemakers need to be exceptionally unreasonable, stubborn, and pathological optimists? Which Ontario wines should you try next, other than Icewine? Why should Ontario be at the top of your list of wine regions to visit? In this episode of the Unreserved Wine Talk podcast, I'm being interviewed by Matthew Gaughan on Matthew's World of Wine and Drink. You can find the wines we discussed at https://www.nataliemaclean.com/winepicks   Highlights Where is Ontario located, and what are the major wine regions within the province? What is the Ontario wine growing season like? When were Ontario's first wineries established, and how has the industry developed since? What is the history of Icewine in Canada, and how is it made? Which notable Ontario white wine varieties should you try? How do Ontario Riesling and Sauvignon Blanc compare to other regions? Which unforgettable red wine varieties produced in Ontario should you try? What should you know about the sparkling wine scene in Ontario? How much of Canadian wine is exported, and what are some of the challenges faced by the industry? How is wine sold and consumed in Canada? What are some of the must-try experiences when visiting Ontario wine regions? How do Canadian wine producers promote their wines abroad?   Key Takeaways Why do Ontario winemakers need to be exceptionally unreasonable, stubborn, and pathological optimists? They need to brave our climate because humid summers can cause rot and mildew, rain right before the grapes are harvested, which, of course, can dilute the flavour, and then winters that can kill the vines. As one winemaker once told me, you can lose the whole field in an afternoon—a whole year's work. Which Ontario wines should you try next, other than Icewine? Riesling is the number one white grape variety in Ontario, and it's really undervalued. Everybody knows Chardonnay as a brand name and feels safer with It, but once they try Riesling, they realize how much flavour they've been missing. Why should Ontario be at the top of your list of wine regions to visit? First, it has stunning scenery and landscapes. Many wineries have restaurants so they offer delicious pairing menus. There are lots of other activities to do as well.   Join me on Instagram, Facebook and YouTube Live Join the live-stream video of this conversation on Wed at 7 pm ET on Instagram Live Video, Facebook Live Video or YouTube Live Video. I want to hear from you! What's your opinion of what we're discussing? What takeaways or tips do you love most from this chat? What questions do you have that we didn't answer? Want to know when we go live? Add this to your calendar: https://www.addevent.com/calendar/CB262621   About Matthew Gaughan & Matthew's World of Wine and Drink As a WSET-certified educator, Matthew Gaughan regularly teaches students to prepare them for exams. His podcast, Matthew's World of Wine and Drink, features episodes focusing on specific topics—grape varieties, regions—to help in that preparation and provide historical and cultural context.         To learn more, visit https://www.nataliemaclean.com/297.

Featuring a slide presentation and related discussion from Dr Kimberly H Allison, including the following topics: Pathological assessment of HER2 and appropriate testing methodologies (0:00) Effect of the DESTINY-Breast04 study on clinical practice (12:32) Relevancy of HER2-ultralow expression and implications of the DESTINY-Breast06 study (22:53) Future directions in the pathological and clinical assessment of HER2-positive breast cancer (31:06) CME information and select publications

Have you ever wondered why you keep finding yourself in toxic relationships despite your best efforts to avoid them?Understanding the dynamics of pathological love relationships, including those involving narcissistic partners, is crucial for anyone navigating the complex emotional and psychological aftermath of a breakup or divorce. This episode delves into how these relationships form and persist, offering insights that could change how you approach healing and personal growth.By listening, you'll learn how to identify the traits that make individuals vulnerable to toxic relationships, understand the manipulative cycle of abuse, and discover effective strategies for healing and moving forward.Tune in now to uncover the crucial insights that could empower you to break free from harmful relationship patterns and reclaim your life.Join us on our podcast as we navigate the complexities of marriage, divorce, separation, and all related legal and emotional aspects, including adultery, alimony, child support, spousal support, timesharing, custody battles, and the financial impact of dissolution of marriage.Disclaimer: This podcast is for informational purposes only and is not an advertisement for legal services.  The information provided on this podcast is not intended to be legal advice.  You should not rely on what you hear on this podcast as legal advice. If you have a legal issue, please contact a lawyer.  The views and opinions expressed by the hosts and guests are solely those of the individuals and do not represent the views or opinions of the firms or organizations with which they are affiliated or the views or opinions of this podcast's advertisers.  This podcast is available for private, non-commercial use only.  Any editing, reproduction, or redistribution of this podcast for commercial use or monetary gain without the expressed, written consent of the podcast's creator is prohibited.

The Power of Now - A Guide to Spiritual Enlightenment with Gilda and Barbara In this episode, we cover "A New Earth - Chapter 4, Section 13 Role-Playing: The Many Faces of the Ego - The Pathological Ego" by Eckhart Tolle Gilda Simonet and Barbara Wainwright have been studying Eckhart Tolle's work for ages. For the podcast purposes, we plan to go through the book from start to finish, reading only one section at a time. There are 122 sections of the book! Join our Facebook Group "The Power of Now - A Guide to Spiritual Enlightenment with Gilda and Barbara" https://www.facebook.com/groups/thepowerofnowaguidetospiritualenlightmentwithgandb/ Contribute to our show here: https://podcasters.spotify.com/pod/show/barbara-wainwright/support Learn more about Barbara Wainwright and our Coaching Courses here: http://www.LifeCoachTrainingOnline.com 800-711-4346 --- Support this podcast: https://podcasters.spotify.com/pod/show/barbara-wainwright/support

In this podcast, Ross Rosenberg, M.Ed, LCPC, CADC, discusses the concept of pathological loneliness, a profound existential pain that individuals with self-love deficit disorder (SLDD), or codependency, experience when they are not in a relationship. Rosenberg explores the roots of this condition, its connection to codependency, and how it manifests as a visceral, bone-aching pain driving individuals into unhealthy relationships to avoid loneliness. He likens SLDD to an addiction, where the "drug" is the relationship itself, not the narcissistic partner. Through this discussion, Rosenberg aims to shed light on the existential crisis faced by those with SLDD and offers insights into his Self-Love Recovery Treatment Program as a path to healing and overcoming this debilitating condition.Support the Show.

How much help is too much? This question hits close to home for many of us. We all want to be there for our friends and family, but there comes a point where we need to step back.  Offering too much help can end up making them dependent on us, preventing them from learning to stand on their own.  It's all about finding that middle ground – being supportive without taking away their chance to learn and grow independently. Today, let's explore the idea of figuring out when our help might be excessive, and whether it's causing any negative impacts on us or the person we're assisting. We've all been in situations where we give a lot without receiving the same in return. To handle this, we need to understand what genuine support truly means.  Always remember that there are times when you don't have to be the hero for everyone. Sometimes, it's important to take care of yourself first before reaching out to help others. What We Discuss:00:00 Intro 00:29 The Savior Complex06:49 How do you know if you're helping someone too much?13:54 Are you helping them get better or make themselves feel better?16:07 What you want for someone is not necessarily what they want18:57 Are you invited to help?21:18 Pathological altruism26:38 What if helping is harming you?30:00 True support Follow Radhi:https://www.instagram.com/radhidevlukia/https://www.youtube.com/channel/UCxWe9A4kMf9V_AHOXkGhCzQhttps://www.facebook.com/radhidevlukia1/https://www.tiktok.com/@radhidevlukiaSee omnystudio.com/listener for privacy information.

Dr. Sarah Schewitz returns to the podcast to talk about pathological love relationships. Dr. Schewitz helps us understand what this type of relationship is, how to know if you're in one, why these types of relationships can be so devastating, and what is necessary to recover and heal.  Dr. Sarah Schewitz is a licensed psychologist specializing in love and relationships. She is the founder of the successful online psychology practice, Couples Learn, which was named by Forbes Health as one of the top 3 online marriage counseling services in 2023. She specializes in healing attachment trauma, understanding the impact of childhood wounds on your relationships, helping couples transform their communication, and rebuilding trust after betrayal. Featured topics: Dr. Schewitz answers, “What is a pathological love relationship [PLR]?” and describes the four identifiers of a PLR (11:18) Signs and red flags that you might be in a pathological love relationship (13:19) The five personality traits of victims who most often are susceptible to this type of relationship (18:42) Why it is necessary to seek out a trauma-informed and educated therapist to aid you in recovery (33:32) Healing from traumatic PLR oftentimes requires a somatic therapy approach (36:06) Learn more about Dr. Sarah Schewitz: Dr. Sarah Schewitz is a licensed psychologist specializing in love & relationships. She is the founder of the successful online psychology practice, Couples Learn, which was named by Forbes Health as one of the top 3 online marriage counseling services in 2023. She specializes in healing attachment trauma, understanding the impact of childhood wounds on your relationships, helping couples transform their communication, and rebuilding trust after betrayal. Dr. Sarah and Couples Learn have been featured on CNN, The Washington Post, Women's Health, Bravo TV, and more.  Resources & Links: Private Coaching with Kate Phoenix Rising: A Divorce Empowerment Collective Couples Learn Episode Link: https://kateanthony.com/podcast/episode-270-pathological-love-relationships-with-dr-sarah-schewitz/ DISCLAIMER: THE COMMENTARY AND OPINIONS AVAILABLE ON THIS PODCAST ARE FOR INFORMATIONAL AND ENTERTAINMENT PURPOSES ONLY AND NOT FOR THE PURPOSE OF PROVIDING LEGAL OR PSYCHOLOGICAL ADVICE. YOU SHOULD CONTACT AN ATTORNEY, COACH, OR THERAPIST IN YOUR STATE TO OBTAIN ADVICE WITH RESPECT TO ANY PARTICULAR ISSUE OR PROBLEM.

Dr. Sarah Schewitz returns to the podcast to talk about pathological love relationships. Dr. Schewitz helps us understand what this type of relationship is, how to know if you're in one, why these types of relationships can be so devastating, and what is necessary to recover and heal.  Dr. Sarah Schewitz is a licensed psychologist specializing in love and relationships. She is the founder of the successful online psychology practice, Couples Learn, which was named by Forbes Health as one of the top 3 online marriage counseling services in 2023. She specializes in healing attachment trauma, understanding the impact of childhood wounds on your relationships, helping couples transform their communication, and rebuilding trust after betrayal. Featured topics: Dr. Schewitz answers, “What is a pathological love relationship [PLR]?” and describes the four identifiers of a PLR (11:18) Signs and red flags that you might be in a pathological love relationship (13:19) The five personality traits of victims who most often are susceptible to this type of relationship (18:42) Why it is necessary to seek out a trauma-informed and educated therapist to aid you in recovery (33:32) Healing from traumatic PLR oftentimes requires a somatic therapy approach (36:06) Learn more about Dr. Sarah Schewitz: Dr. Sarah Schewitz is a licensed psychologist specializing in love & relationships. She is the founder of the successful online psychology practice, Couples Learn, which was named by Forbes Health as one of the top 3 online marriage counseling services in 2023. She specializes in healing attachment trauma, understanding the impact of childhood wounds on your relationships, helping couples transform their communication, and rebuilding trust after betrayal. Dr. Sarah and Couples Learn have been featured on CNN, The Washington Post, Women's Health, Bravo TV, and more.  Resources & Links: Private Coaching with Kate Phoenix Rising: A Divorce Empowerment Collective Couples Learn Episode Link: https://kateanthony.com/podcast/episode-270-pathological-love-relationships-with-dr-sarah-schewitz/ DISCLAIMER: THE COMMENTARY AND OPINIONS AVAILABLE ON THIS PODCAST ARE FOR INFORMATIONAL AND ENTERTAINMENT PURPOSES ONLY AND NOT FOR THE PURPOSE OF PROVIDING LEGAL OR PSYCHOLOGICAL ADVICE. YOU SHOULD CONTACT AN ATTORNEY, COACH, OR THERAPIST IN YOUR STATE TO OBTAIN ADVICE WITH RESPECT TO ANY PARTICULAR ISSUE OR PROBLEM.

They'll shake your hand while pissing on your leg, plead and then pulverize promises, and generally give the sense that they're one hundred people who share a face. But why? Let's talk about narcissist personality structuring that ranges from neurotic to psychopathic, but never hits the mark of "maturity." Meanwhile, creating the condition I've titled simply: There is no Integrity without Integration. Into this talk? Come hang out, there's been plenty more at patreon.com/traumatizedmotherfuckers or the new Spotify exclusive subscription option found here.

This week; in the hush money case, Trump skirts the limited gag order and goes after Judge Merchan's daughter in multiple posts.Mike Roman is subpoenaed by Arizona prosecutors investigating the fraudulent electors scheme.Jeffrey Clark's and John Eastman's disbarment proceedings are underway. And more!FCI Miami Commissary https://www.bop.gov/locations/institutions/mia/mia_legal_activities.pdfAllison Gillhttps://post.news/@/MuellerSheWrotehttps://twitter.com/MuellerSheWrotePete Strzokhttps://twitter.com/petestrzokThe Podcasthttps://twitter.com/aisle45podWant to support this podcast and get it ad-free and early?Go to: https://www.patreon.com/aisle45podTell us about yourself and what you like about the show - http://survey.podtrac.com/start-survey.aspx?pubid=BffJOlI7qQcF&ver=short Allison Gillhttps://post.news/@/MuellerSheWrotehttps://twitter.com/MuellerSheWrotePete Strzokhttps://twitter.com/petestrzokThe Podcasthttps://twitter.com/aisle45podWant to support this podcast and get it ad-free and early?Go to: https://www.patreon.com/aisle45podTell us about yourself and what you like about the show - http://survey.podtrac.com/start-survey.aspx?pubid=BffJOlI7qQcF&ver=short

Kate interviews Christopher Cassel, Director and Executive Producer of the Peacock Original true crime documentary Pathological: The Lies of Joran Van Der Sloot. The 90-minute documentary delves into Joran van der Sloot's lifelong pattern of violence and pathological lying through rare interviews and new insights years after he brutally murdered American Natalee Holloway and Peruvian Stephany Flores. Reality Life with Kate CaseyPatreon: http://www.patreon.com/katecaseyTwitter: https://twitter.com/katecaseyInstagram: http://www.instagram.com/katecaseycaTik Tok: http://www.tiktok.com/itskatecaseyCameo: https://cameo.com/katecaseyFacebook Group: https://www.facebook.com/groups/113157919338245Amazon.com: www.amazon.com/shop/katecaseySee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Headlines for February 20, 2024; “Borders on Pathological”: Trump Must Pay $450 Million for Lying to Lenders in Fraud Case; More Than 50 Countries Argue Before World Court Against Israeli Occupation of Palestine; “What I Saw Wasn’t War — It Was Annihilation,” Says U.S. Doctor Who Volunteered in Gaza Hospital

Trump's crappy sneakers. Trump booed at Sneaker Con. Trump was found liable for nearly a half billion dollars for committing widespread business fraud. Engoron describes Trump's pathological response. Eric Trump's whiny lament. Where will he get the money and how badly is Trump compromised and conflicted by this amount of debt? Trump's fundraising money is also being drained. Engoron reversed his order about Trump's businesses. Trump has to install an independent director of compliance -- a baby sitter. Trump supports a 16 week abortion ban. Meet The Press committed journalistic malpractice -- again! Ezra Klein's NYT op/ed and Biden's fitness for office. With Buzz Burbank, music by Karma and the Killjoys, Powder Pink and Sweet, and more!See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.